ANRO (Alto Neuroscience) OCF Margin %: 0.00% (As of Mar. 2026)


ANRO Alto Neuroscience Inc ANRO
12 GF Score
Price $25.30
! 1 Warning Sign
View Full Analysis

What is Alto Neuroscience OCF Margin %?

Alto Neuroscience ANRO +1.57% 12 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates ANRO with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 960 Biotechnology companies, Alto Neuroscience ranks worse than 104166.56% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Alto Neuroscience's Cash Flow from Operations for the three months ended in Mar. 2026 was $-27.09 Mil. Alto Neuroscience's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Alto Neuroscience's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Alto Neuroscience's current OCF Yield % is -7.02%.

The historical rank and industry rank for Alto Neuroscience's OCF Margin % or its related term are showing as below:


During the past 5 years, the highest OCF Margin % of Alto Neuroscience was -4410.48%. The lowest was -4410.48%. And the median was -4410.48%.

ANRO's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Alto Neuroscience OCF Margin % Related Terms

Alto Neuroscience OCF Margin % Historical Data

* Premium members only.

The historical data trend for Alto Neuroscience's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alto Neuroscience OCF Margin % Chart

Alto Neuroscience Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
-4,410.48 0.00 0.00 0.00 0.00

Alto Neuroscience Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ANRO
12GF Score
Alto Neuroscience Inc ANRO
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alto Neuroscience OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Alto Neuroscience's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-51.769/0
= %

Alto Neuroscience's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-27.091/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Alto Neuroscience (ANRO) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Alto Neuroscience and its competitors. According to the industry distribution chart, Alto Neuroscience ranks #999999 out of 960 companies in the Biotechnology industry.
Is Alto Neuroscience's OCF Margin % too high?
Alto Neuroscience's current OCF Margin % is 0.00%. Based on the distribution chart, Alto Neuroscience ranks #999999 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alto Neuroscience has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alto Neuroscience's OCF Margin % compare to MRVI and BBOT?
According to the Biotechnology industry distribution chart, Alto Neuroscience ranks #999999 out of 960 companies for OCF Margin %. This places Alto Neuroscience in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Alto Neuroscience and its competitors. Alto Neuroscience's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alto Neuroscience stock overvalued right now?
Alto Neuroscience (ANRO) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Alto Neuroscience's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Alto Neuroscience (ANRO), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alto Neuroscience Business Description

Address 650 Castro Street, Suite 450, Mountain View, CA, USA, 94041
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
12GF Score

Get the complete analysis for ANRO

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.30
Price